Xenon Pharmaceuticals is a clinical-stage biotech with its pipeline concentrated in the azetukalner program, where analysts see roughly 54% upside to current prices, but below-average business quality and inconsistent earnings execution make this a speculative hold requiring confirmation before new capital.
Thesis pillars
- Azetukalner Pipeline Concentration→Stable
- Analyst Upside Vs Quality Floor→Stable
- Earnings Miss Pattern↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $38.23: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 10.07; Below-average business quality; Below long-term trend.
Xenon Pharmaceuticals is a pre-revenue neuroscience biotech with no marketed products, advancing azetukalner — a Kv7 potassium channel opener — through Phase 3 studies in epilepsy (FOS, PGTCS) and neuropsychiatric disorders (MDD, BPD). Net losses were $345.9 million in 2025,... Read more
Sell if holding. Engine safety override at $38.23: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 10.07; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 73. Score 5.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: speculative.
About Xenon Pharmaceuticals Inc.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals' pipeline centers on azetukalner, a Kv7 potassium channel opener in Phase 3 studies for focal onset seizures (FOS), primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. The company reported net losses of $345.9 million in 2025 and accumulated a deficit of $1,245.4 million through December 31, 2025. Topline data from the X-TOLE2 FOS study, enrolling 380 patients, were expected in the first half of March 2026.
Xenon generates no product revenue and finances operations through equity offerings, debt, and collaboration receipts. The azetukalner epilepsy program spans FOS via X-TOLE2 (380 patients enrolled, topline readout H1 2026) and X-TOLE3 (international support; non-Japan enrollment expected to complete in 2026), plus PGTCS via X-ACKT (targeting 160 patients). The neuropsychiatric program includes X-NOVA2 and X-NOVA3 for MDD (roughly 450 patients each, with X-NOVA2 topline data expected H1 2027) and a separate BPD study targeting 400 patients. Phase 2b X-TOLE results showed azetukalner 25 mg achieved a median 52.8% reduction in monthly focal seizure frequency versus 18.2% for placebo, meeting the primary endpoint. Patents covering crystalline forms of azetukalner drug substance are expected to expire in 2040 and methods of administration patents in 2039. A collaboration with Neurocrine Biosciences, entered in December 2019, advanced NBI-921355 into Phase 1 for epilepsy, while early-stage pain candidates XEN1701 (Nav1.7) and XEN1120 (Kv7) entered Phase 1 studies in 2025 with completion expected in 2026.
Show full overview
Azetukalner constitutes all of Xenon's commercial potential, with the 10-K stating the company has no previous experience completing a Phase 3 clinical study or NDA submission. Each Phase 3 readout — X-TOLE2 in FOS (anticipated H1 2026), X-NOVA2 in MDD (H1 2027), and the BPD study — represents an independent binary event that could materially reset valuation across the entire franchise. A failure in any single indication would not invalidate the others mechanically, but could reduce confidence in the Kv7 mechanism and constrain available capital for the remaining programs, compounding the binary risk profile across all outstanding studies.
See also: Healthcare · Biotechnology
From Xenon Pharmaceuticals Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Xenon Pharmaceuticals Inc.
Latest news
- NEWS Xenon Pharmaceuticals Announces Participation in Upcoming Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS Xenon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 — fiscal.ai Nov 2, 2026
- NEWS Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — fiscal.ai Oct 30, 2026 neutral
- NEWS Xenon Pharmaceuticals Announces Positive Phase 1 Results and Preclinical Data for Acute Pain Candidates XEN1701 and XEN1 — fiscal.ai Oct 29, 2026 positive
- NEWS Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association Fo — benzinga Oct 29, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-04T11:54:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineazetukalner10-K Item 1A: 'We have no marketed proprietary products and are advancing clinical development through Phase 3 clinical studies for our azetukalner program'
Material Events(8-K, last 90d)
- 2026-06-03Item 5.02LOWShareholders approved the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan at the June 2, 2026 annual meeting, replacing the Amended and Restated 2014 Equity Incentive Plan. Routine compensatory arrangement; no officer departure involved.SEC filing →
- 2026-04-13Item 5.02LOWCompany amended 2025 Inducement Equity Plan on April 7, 2026 to increase reserved shares from 900,000 to 1,175,000 for inducement grants to new hires. Approved without shareholder vote under Nasdaq Rule 5635(c)(4). No officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.23: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 10.07; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 73. Prior stop was $35.77. Score 5.5/10, moderate confidence.
Analyst target: $64.58 (+68.9% upside). Prior stop was $35.77. Stop-loss: $35.77.
Concentration risk — Pipeline: azetukalner; Quality below floor (1.6 < 4.0).
Xenon Pharmaceuticals Inc. trades at a P/E of N/A (forward -8.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
25 analysts rate XENE, with a consensus score of 4.4/5. 16 analysts publish price targets averaging $72.
What does Xenon Pharmaceuticals Inc. do?Xenon Pharmaceuticals is a pre-revenue neuroscience biotech with no marketed products, advancing azetukalner — a Kv7...
Xenon Pharmaceuticals is a pre-revenue neuroscience biotech with no marketed products, advancing azetukalner — a Kv7 potassium channel opener — through Phase 3 studies in epilepsy (FOS, PGTCS) and neuropsychiatric disorders (MDD, BPD). Net losses were $345.9 million in 2025, accumulating a deficit of $1,245.4 million through December 31, 2025. A collaboration with Neurocrine Biosciences covers Nav channel programs including NBI-921355 in Phase 1.